Drug Profile
MB 11319
Alternative Names: MB11319Latest Information Update: 30 Mar 2016
Price :
$50
*
At a glance
- Originator Mazence
- Developer KT&G Life Sciences
- Class Anti-inflammatories; Antiallergics; Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity; Prostate cancer; Prostatitis
Most Recent Events
- 30 Mar 2016 No recent reports on development identified - Phase-I for Hypersensitivity, Prostatitis and Prostate cancer in South Korea (unspecified route)
- 31 Oct 2013 Phase-I clinical trials in Hypersensitivity, Prostatitis and Prostate cancer in South Korea (unspecified route)
- 30 Mar 2012 Mazence is now called KT&G Life Sciences